54 terminated. 54 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 54 | Terminated 54 |
| Phase 2 | 5 | Terminated 5 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) - Myelodysplastic Syndromes(MDS) | Phase 3 | Terminated | TJ Biopharma Co., Ltd. | 10 | 2023-03-30 | 2025-04-27 |
| A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG) - Severe Aplastic Anemia | Phase 3 | Terminated | Boston Children's Hospital | 53 | 2023-01-25 | 2026-10-19 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 3 | 2022-10-06 | 2025-04-08 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 177 | 2021-05-26 | 2025-10-02 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 252 | 2021-05-24 | 2025-10-21 |
| Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome Tamibarotene, Placebo, Azacitidine - Myelodysplastic Syndromes | Phase 3 | Terminated | Syros Pharmaceuticals | 246 | 2021-02-08 | 2025-04-10 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Magrolimab, Azacitidine, Placebo - Myelodysplastic Syndromes | Phase 3 | Terminated | Gilead Sciences | 539 | 2020-09-09 | 2024-06-27 |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Sabatolimab, Azacitidine, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 530 | 2020-06-08 | 2026-01-13 |
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality Optimal medical treatment, usual clinical practice - Chronic Myeloid Leukemia (CML) | Phase 3 | Terminated | University Hospital, Angers | 80 | 2019-12-20 | 2025-03-17 |
| REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability. REGN3918 - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 24 | 2019-12-03 | 2023-06-12 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Panobinostat Maintenance After HSCT fo High-risk AML and MDS Panobinostat - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Terminated | Goethe University | 52 | 2018-07-24 | 2023-02-16 |
| Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden Roxadustat, Placebo - Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia | Phase 3 | Terminated | Kyntra Bio | 184 | 2018-01-29 | 2024-08-01 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) Diet - Leukemia, Myelodysplastic Syndromes | Phase 3 | Terminated | University of Florida | 217 | 2017-08-18 | 2025-04-07 |
| Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia Dasatinib 100 MG [Sprycel], Nilotinib 150mg oral capsule [Tasigna] - Chronic Myeloid Leukemia - Chronic Phase | Phase 3 | Terminated | Hamad Medical Corporation | 10 | 2017-08-03 | 2019-01-23 |
| rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study rVA576 - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | AKARI Therapeutics | 15 | 2017-03-13 | 2025-04-10 |
Showing 20 of 54. Sign in to see all of them.
Myelodysplastic Syndromes (23) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15) · Myeloproliferative Disorders (12) · Leukemia (10) · Leukemia, Myeloid, Acute (9) · Leukemia, Myeloid, Chronic-Phase (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Primary Myelofibrosis (8) · Graft vs Host Disease (5) · Leukemia, Myeloid (5) · Leukemia, Myelomonocytic, Chronic (5) · Anemia (4) · Hematologic Diseases (4) · Lymphoma (4)
Hemic and Lymphatic Diseases (54) · Hematologic Diseases (50) · Neoplasms (30) · Neoplasms by Histologic Type (28) · Pathological Conditions, Signs and Symptoms (26) · Leukemia, Myeloid (24) · Chronic Disease (23) · Disease Attributes (23) · Pathologic Processes (23) · Leukemia (20) · Myeloproliferative Disorders (18) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9)
Imatinib Mesylate (7) · Cyclophosphamide (6) · nilotinib (6) · Azacitidine (5) · Methotrexate (4) · ruxolitinib (4) · Busulfan (3) · Whole-Body Irradiation (3) · fludarabine (3) · fludarabine phosphate (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Cyclosporine (2) · Dasatinib (2) · Hydroxyurea (2) · parsaclisib (2)
Novartis Pharmaceuticals (7) · Ariad Pharmaceuticals (2) · CTI BioPharma (2) · European Society for Blood and Marrow Transplantation (2) · Incyte Corporation (2) · Kiadis Pharma (2) · Merck Sharp & Dohme LLC (2) · Regeneron Pharmaceuticals (2) · AKARI Therapeutics (1) · Alberta Children's Hospital (1) · Alliance for Clinical Trials in Oncology (1) · Baxalta now part of Shire (1) · Bellicum Pharmaceuticals (1) · Boston Children's Hospital (1) · Bristol-Myers Squibb (1)
United States (30) · Germany (19) · Italy (19) · Canada (17) · France (17) · Belgium (16) · United Kingdom (15) · Australia (13) · Spain (12) · Netherlands (11) · Czechia (10) · Poland (10) · Austria (9) · Hungary (9) · Israel (9)
Afanasyer Boris (1) · Albert Assad, M.D (1) · Albert Assad, M.D. (1) · Alessandro Levis, MD (1) · Allione Bernardino (1) · Andrea Velardi, MD (1) · Augustin Ferrant, MD (1) · Axel R Zander, MD (1)
PMID 33275766, PMID 19270260, PMID 21233311, PMID 22315495, PMID 23216616, PMID 23515925, PMID 24472814, PMID 24859364, PMID 27083332, PMID 28380315, PMID 30305280, PMID 31582549, PMID 34551507, PMID 34699069, PMID 34724251, PMID 36888930, PMID 37083373, PMID 38065202, PMID 38838026, PMID 39400386, PMID 40227676, PMID 40334070, PMID 41406403, PMID 42316774, PMID 42441929
2015 (2), 2019 (2), 1UG3HL157564-01A1 (1), 2005 (1), 2008 (1), 2014 (1), 2016 (1), 2018 (1), P30CA069533 (1), U01HL069294 (1), U10CA031946 (1), U24CA076518 (1), U24HL157560 (1)